Lifecore Biomedical (LFCR) earnings
In the quarter ended June 2026, Lifecore Biomedical had revenue of $34M, down 2.8% on a year earlier, and diluted EPS of -0.19.
On August 5, 2026 it reported EPS of -0.19 against an estimate of -0.17 (missed).
Report dates
| Report | Date | Time | EPS estimate | EPS reported |
|---|---|---|---|---|
| Last | Wed Aug 5, 2026 | — | -0.17 | -0.19 |
Dates from company announcements and exchange calendars; estimates are the consensus where available. See the full earnings calendar.
Quarterly results
The last 12 quarters from Lifecore Biomedical's 10-Q and 10-K filings with the SEC. Growth is against the same quarter a year earlier. EPS here is GAAP diluted EPS as filed; the reported EPS compared with estimates above can be on the company's adjusted basis, so the two can differ.
| Quarter ended | Revenue | Growth | EPS (diluted) | Growth | Op. margin | Filed |
|---|---|---|---|---|---|---|
| Jun 30, 2026 | $34M | -2.8% | -0.19 | — | 7.5% | 2026-08-05 |
| Mar 31, 2026 | $23M | -28.8% | -0.43 | — | -20.1% | 2026-05-06 |
| Sep 30, 2025 | $31M | +25.9% | -0.29 | — | -9.9% | 2025-11-06 |
| May 31, 2025 | $36M | -3.8% | -0.06 | — | 14.6% | 2026-08-05 |
| Feb 28, 2025 | $35M | -1.5% | -0.42 | -200.0% | -25.7% | 2025-04-03 |
| Nov 30, 2024 | $33M | +8.0% | -0.25 | -164.1% | -6.0% | 2025-01-02 |
| Aug 31, 2024 | $25M | +0.7% | -0.53 | — | -46.9% | 2024-10-04 |
| May 31, 2024 | $38M | +21.6% | — | — | 5.7% | 2024-08-26 |
| Feb 29, 2024 | $36M | +34.5% | 0.42 | — | -2.5% | 2024-08-09 |
| Nov 30, 2023 | $30M | +37.9% | 0.39 | — | -4.9% | 2024-08-09 |
| Aug 31, 2023 | $25M | +3.4% | -0.35 | — | -35.1% | 2024-08-09 |
| May 31, 2023 | $31M | +10.8% | -1.32 | — | -21.3% | 2024-03-20 |
Questions
How did Lifecore Biomedical do last quarter?
In the quarter ended June 2026, Lifecore Biomedical had revenue of $34M, down 2.8% on a year earlier, and diluted EPS of -0.19.
From Lifecore Biomedical's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.